Meeder Asset Management’s Kronos Bio KRON Stock Holding History

Meeder Asset Management’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3	Closed	–	–	2258
2022 Q2	$0	Hold	3	–	–	﹤0.01%	2316
2022 Q1	$0	Buy	+3	New	+$26	﹤0.01%	2426

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Meeder Asset Management's KRON Position: Q3 2022 in Review

Meeder Asset Management sold out of Kronos Bio (KRON) in Q3 2022, closing a stake of 3 shares.

Meeder Asset Management first reported a position in KRON in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 96 funds tracked by Wall St. Rank hold KRON as of Q3 2022.

Meeder Asset Management reported no remaining Kronos Bio position as of Q3 2022 after selling out during the quarter.
Meeder Asset Management sold 3 Kronos Bio shares in Q3 2022.
Meeder Asset Management first reported a position in Kronos Bio in Q1 2022 and held it in 2 quarters.
Meeder Asset Management's Kronos Bio position peaked at $0 in Q2 2022.
96 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2022.

Based on Meeder Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.